- Home
- PASG vs CALC Comparison
PASG vs CALC Comparison
Compare PASG & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PASG
- CALC
- Stock Information
- Founded
- PASG 2017
- CALC 2011
- Country
- PASG United States
- CALC United States
- Employees
- PASG N/A
- CALC N/A
- Industry
- PASG Biotechnology: Pharmaceutical Preparations
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- PASG Health Care
- CALC Health Care
- Exchange
- PASG Nasdaq
- CALC Nasdaq
- Market Cap
- PASG 31.1M
- CALC 26.7M
- IPO Year
- PASG 2020
- CALC N/A
- Fundamental
- Price
- PASG $0.45
- CALC $1.68
- Analyst Decision
- PASG Strong Buy
- CALC Strong Buy
- Analyst Count
- PASG 3
- CALC 3
- Target Price
- PASG $7.67
- CALC $16.33
- AVG Volume (30 Days)
- PASG 387.0K
- CALC 24.2K
- Earning Date
- PASG 05-13-2025
- CALC 05-14-2025
- Dividend Yield
- PASG N/A
- CALC N/A
- EPS Growth
- PASG N/A
- CALC N/A
- EPS
- PASG N/A
- CALC N/A
- Revenue
- PASG N/A
- CALC N/A
- Revenue This Year
- PASG N/A
- CALC N/A
- Revenue Next Year
- PASG N/A
- CALC N/A
- P/E Ratio
- PASG N/A
- CALC N/A
- Revenue Growth
- PASG N/A
- CALC N/A
- 52 Week Low
- PASG $0.26
- CALC $1.43
- 52 Week High
- PASG $1.33
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- PASG 60.67
- CALC 43.11
- Support Level
- PASG $0.40
- CALC $1.61
- Resistance Level
- PASG $0.52
- CALC $1.73
- Average True Range (ATR)
- PASG 0.05
- CALC 0.10
- MACD
- PASG 0.02
- CALC -0.02
- Stochastic Oscillator
- PASG 71.19
- CALC 16.26
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.